PL3474904T3 - Otrzymywanie przeciwciał monoklonalnych znakowanych 212pb - Google Patents
Otrzymywanie przeciwciał monoklonalnych znakowanych 212pbInfo
- Publication number
- PL3474904T3 PL3474904T3 PL17732126.2T PL17732126T PL3474904T3 PL 3474904 T3 PL3474904 T3 PL 3474904T3 PL 17732126 T PL17732126 T PL 17732126T PL 3474904 T3 PL3474904 T3 PL 3474904T3
- Authority
- PL
- Poland
- Prior art keywords
- obtaining
- monoclonal antibodies
- labelled monoclonal
- labelled
- antibodies
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
- A61K51/1051—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from breast, e.g. the antibody being herceptin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
- A61K51/1096—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies radioimmunotoxins, i.e. conjugates being structurally as defined in A61K51/1093, and including a radioactive nucleus for use in radiotherapeutic applications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/008—Peptides; Proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Oncology (AREA)
- Cell Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16176263 | 2016-06-24 | ||
| PCT/EP2017/065508 WO2017220767A1 (en) | 2016-06-24 | 2017-06-23 | Preparation of 212pb labeled monoclonal antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3474904T3 true PL3474904T3 (pl) | 2024-12-16 |
Family
ID=56263569
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL17732126.2T PL3474904T3 (pl) | 2016-06-24 | 2017-06-23 | Otrzymywanie przeciwciał monoklonalnych znakowanych 212pb |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US11306038B2 (pl) |
| EP (1) | EP3474904B1 (pl) |
| JP (1) | JP7176958B2 (pl) |
| CN (1) | CN109310789B (pl) |
| AU (1) | AU2017281649B2 (pl) |
| CA (1) | CA3026599A1 (pl) |
| ES (1) | ES2991349T3 (pl) |
| IL (1) | IL263808B2 (pl) |
| MX (1) | MX2018016121A (pl) |
| PL (1) | PL3474904T3 (pl) |
| WO (1) | WO2017220767A1 (pl) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10704021B2 (en) | 2012-03-15 | 2020-07-07 | Flodesign Sonics, Inc. | Acoustic perfusion devices |
| US9725710B2 (en) | 2014-01-08 | 2017-08-08 | Flodesign Sonics, Inc. | Acoustophoresis device with dual acoustophoretic chamber |
| US11708572B2 (en) | 2015-04-29 | 2023-07-25 | Flodesign Sonics, Inc. | Acoustic cell separation techniques and processes |
| US11377651B2 (en) | 2016-10-19 | 2022-07-05 | Flodesign Sonics, Inc. | Cell therapy processes utilizing acoustophoresis |
| US11214789B2 (en) | 2016-05-03 | 2022-01-04 | Flodesign Sonics, Inc. | Concentration and washing of particles with acoustics |
| JP2021507561A (ja) | 2017-12-14 | 2021-02-22 | フロデザイン ソニックス, インク.Flodesign Sonics, Inc. | 音響トランスデューサドライバ及びコントローラ |
| MX2022006638A (es) | 2019-12-05 | 2022-07-19 | Sciencons AS | Producción de 212pb altamente purificados. |
| IL310474A (en) | 2021-08-11 | 2024-03-01 | Nuclear Res And Consultancy Group | System and method of production and isolation of charged radionuclides |
| JP2025507661A (ja) * | 2022-02-24 | 2025-03-21 | アルファ タウ メディカル リミテッド | 対流強化拡散アルファエミッタ放射線療法 |
| JP7816003B2 (ja) * | 2022-06-06 | 2026-02-18 | Jfeエンジニアリング株式会社 | 放射性物質の標識方法 |
| US20240091705A1 (en) * | 2022-09-16 | 2024-03-21 | Viewpoint Molecular Targeting, Inc. | Removal of free-unlabeled cationic and anionic solution phase radionuclides from radiopharmaceuticals using solid-phase extraction techniques |
| US20250332297A1 (en) | 2024-01-31 | 2025-10-30 | Molecular Partners Ag | Dll3-specific binding constructs and their use in radiotherapy |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NO312708B1 (no) * | 2000-02-21 | 2002-06-24 | Anticancer Therapeutic Inv Sa | Radioaktive liposomer til terapi |
| DE10040771A1 (de) | 2000-08-21 | 2002-03-14 | Altmann Therapie Gmbh & Co Kg | Neue, 224Ra enthaltende, radiotherapeutisch wirksame Formulierungen und Verfahren zu ihrer Herstellung |
| DE10347459B3 (de) * | 2003-10-13 | 2005-05-25 | Actinium Pharmaceuticals, Inc. | Radium-Target sowie Verfahren zu seiner Herstellung |
| SI1853718T1 (sl) * | 2005-02-15 | 2016-02-29 | Duke University | Protitelesa anti-CD19 in uporabe v onkologiji |
| WO2012032043A1 (en) * | 2010-09-07 | 2012-03-15 | Areva Med Llc | 212 pb imaging |
| ES2657388T3 (es) * | 2015-02-26 | 2018-03-05 | Sciencons AS | Disoluciones radiofarmacéuticas con propiedades ventajosas |
| US9433690B1 (en) * | 2015-02-26 | 2016-09-06 | Sciencons AS | Radiopharmaceutical solutions with advantageous properties |
| DK3261681T3 (da) | 2015-02-26 | 2020-04-27 | Sciencons AS | Radiofarmaceutiske opløsninger med fordelagtige egenskaber |
-
2017
- 2017-06-23 US US16/307,811 patent/US11306038B2/en active Active
- 2017-06-23 AU AU2017281649A patent/AU2017281649B2/en active Active
- 2017-06-23 ES ES17732126T patent/ES2991349T3/es active Active
- 2017-06-23 CN CN201780038560.8A patent/CN109310789B/zh active Active
- 2017-06-23 WO PCT/EP2017/065508 patent/WO2017220767A1/en not_active Ceased
- 2017-06-23 JP JP2018566836A patent/JP7176958B2/ja active Active
- 2017-06-23 EP EP17732126.2A patent/EP3474904B1/en active Active
- 2017-06-23 PL PL17732126.2T patent/PL3474904T3/pl unknown
- 2017-06-23 IL IL263808A patent/IL263808B2/en unknown
- 2017-06-23 MX MX2018016121A patent/MX2018016121A/es unknown
- 2017-06-23 CA CA3026599A patent/CA3026599A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| IL263808A (en) | 2019-02-03 |
| EP3474904B1 (en) | 2024-08-07 |
| WO2017220767A1 (en) | 2017-12-28 |
| CN109310789A (zh) | 2019-02-05 |
| EP3474904A1 (en) | 2019-05-01 |
| AU2017281649B2 (en) | 2023-07-27 |
| IL263808B2 (en) | 2025-04-01 |
| US20190194087A1 (en) | 2019-06-27 |
| JP7176958B2 (ja) | 2022-11-22 |
| CN109310789B (zh) | 2021-12-03 |
| US11306038B2 (en) | 2022-04-19 |
| AU2017281649A1 (en) | 2019-01-03 |
| IL263808B1 (en) | 2024-12-01 |
| ES2991349T3 (es) | 2024-12-03 |
| JP2019523232A (ja) | 2019-08-22 |
| NZ749058A (en) | 2025-07-25 |
| CA3026599A1 (en) | 2017-12-28 |
| MX2018016121A (es) | 2019-05-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL272227A (en) | Anti-tigit antibodies | |
| IL269405A (en) | Anti-sirp alpha antibodies | |
| IL272274A (en) | B7-h4 antibodies and methods of use thereof | |
| DK3625259T3 (da) | Anti-sirpalpha-antistoffer | |
| EP3661558A4 (en) | ANTI-IL1RAP ANTIBODIES | |
| PT3606954T (pt) | Anticorpos anti-lag3 | |
| EP3569709A4 (en) | ANTI-GPC3 ANTIBODIES | |
| EP3532489A4 (en) | ANTI-TL1A NEUTRALIZING MONOCLONAL ANTIBODIES | |
| DK3455257T3 (da) | Anti-pd-l1-antistoffer | |
| EP3387442A4 (en) | HUMANIZED ANTI-CD73 ANTIBODIES | |
| HUE051700T2 (hu) | Anti-PD-1 antitestek | |
| EP3481869A4 (en) | ANTI-CD73 ANTIBODIES | |
| EP3691447A4 (en) | ANTI-TRANSTHYRETINE ANTIBODY | |
| DK3332006T3 (da) | Hidtil ukendte anti-PD-L1-antistoffer | |
| PL3474904T3 (pl) | Otrzymywanie przeciwciał monoklonalnych znakowanych 212pb | |
| DK3441086T3 (da) | Monoklonalt anti-PD-1-antistof | |
| KR20180085002A (ko) | 인간화된 항-cll-1 항체 | |
| DK3606961T3 (da) | Garp-tgf-beta-antistoffer | |
| DK3452513T3 (da) | Humaniserede anti-il-ir3-antistoffer | |
| IL256097A (en) | Antibody epitope | |
| DK3649152T3 (da) | ROR1-antistoffer | |
| HUE061076T2 (hu) | Humanizált anti-C1s ellenanyagok alkalmazási eljárások | |
| EP3487518A4 (en) | HUMANIZED MONOCLONAL ANTIBODIES TARGETING VE-PTP (HPTP-SS) | |
| EP3532034A4 (en) | ANTI-APOE ANTIBODY | |
| EP3567053A4 (en) | ANTI-CLAUDINE-2 MONOCLONAL ANTIBODY |